RBR-8nwxhs4尚未招募不适用
Homologous recombination deficiency (HRD) test validation by NGS methodology at Oncoclínicas Precision Medicine laboratory in Brazil
Oncoclinicas do Brasil Serviços Médicos S.A0 个研究点开始时间: 2023年9月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18Y 至 0（—）
- 性别
- Female
入选标准
- •Patients > 18 years old; diagnosed with high grade serous ovarian cancer; platinum-sensitive; mutant or wild type for germline or somatic HRR genes based on OCPM Next Generation Sequencing (NGS) panels.
排除标准
- •Patient that do not accept to sign the informed consent
研究者
相似试验
Unknown
不适用
A Training Set for the HRD Model in EOCBRCA MutationLoss of HeterozygosityPrognosisPlatinum ResistanceHomologous Recombination DeficiencyEpithelial Ovarian CancerNCT04651933Lei Li200
已完成
不适用
Homologous Recombination Inquiry Through Ovarian Malignancy InvestigationsFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT03159572Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan996
Unknown
不适用
Homologous Recombination Deficiency in Chinese Ovarian Cancer PatientsHRDPARP InhibitorOvarian CancerNCT05044091Xiaoxiang Chen100
招募中
1 期
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.Metastatic Breast Cancer HR+, HER2-MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2022-502372-22-01nicancer1,080
尚未招募
不适用
Diagnostic test (ReceptIVFity) for recognition of embryo implantation failure in practice.NL-OMON45617Voortplantingsgeneeskunde303